ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

Grant

Date/time Interval

  • June 1, 2018 - May 31, 2019
  • Total Award Amount

  • 17776.00
  • Direct Costs

  • 14108.00
  • Sponsor Award Id

  • Contributor

  • Alva, Elizabeth   Investigator  
  • Aye, Jamie   Investigator  
  • Friedman M.D., Gregory   Principal Investigator  
  • Galtarossa Xavier, Ana   Investigator  
  • Johnston, Emily   Investigator  
  • Kutny M.D., Matthew   Investigator  
  • Liang, Wayne   Investigator  
  • Metrock, Laura   Investigator  
  • Whelan M.D., Kimberly   Investigator